Skip to content

Clinical trials

Phase 4 ST Elevation Myocardial Infarction trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: ST Elevation Myocardial Infarction Phase: Phase 4 Clear all

114 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20041
20062
20072
20093
20102
201110
20125
20133
201412
201510
20164
201710
20185
20196
20203
20218
20227
20236
20242
20254
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed50
Unknown status36
Recruiting10
Not yet recruiting7
Withdrawn5
Active, not recruiting4
Terminated2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
RenJi Hospital4
University of Patras3
Azienda Policlinico Umberto I2
Beijing Anzhen Hospital2
Careggi Hospital2
Gyeongsang National University Hospital2
Henan Institute of Cardiovascular Epidemiology2
Insel Gruppe AG, University Hospital Bern2
InspireMD2
Maasstad Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
ST Elevation Myocardial Infarction114
Myocardial Infarction22
Non-ST Elevated Myocardial Infarction20
Acute Coronary Syndrome18
Angina, Unstable9
Cardiovascular Diseases7
Coronary Artery Disease7
Coronary Disease4
Thrombosis3
Ventricular Remodeling3

Trials

Showing 76 to 100 of 114. Each trial links to its page on Pharma Observatory.

14 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.